Meridian Bioscience Inc. (VIVO)
(Delayed Data from NSDQ)
$11.51 USD
-0.48 (-4.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.51 USD
-0.48 (-4.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
New Strong Buy Stocks for February 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Cardiovascular System's (CSII) OAS Cures 1st Patient in Europe
by Zacks Equity Research
Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.
Boston Scientific (BSX) Hurt by Product Recall, Conversion
by Zacks Equity Research
Barring MedSurg, organic revenues at each of Boston Scientific (BSX) core segments and geographies are down in Q4 but the magnitude of this decline is lower than Q3.
Is Meridian Bioscience (VIVO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (VIVO) Outperforming Other Medical Stocks This Year?
Meridian Bioscience (VIVO) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 54.76% and 1.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Meridian (VIVO) Might Surprise This Earnings Season
by Zacks Equity Research
Meridian (VIVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Biotech Bonanza: COVID Launches Science at Warp Speed
by Kevin Cook
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Cigna (CI) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna's (CI) fourth-quarter results are likely to reflect strong performance across the business portfolio and lower SG&A costs, partly offset by continued COVID-19 related expenses.
What's in Store for Meridian Bioscience's (VIVO) Q1 Earnings?
by Zacks Equity Research
Meridian Bioscience's (VIVO) fiscal first-quarter results are likely to reflect strong performance by Life Science business line.
Meridian Bioscience (VIVO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Meridian Bioscience (VIVO) closed at $22.10, marking a +1.33% move from the previous day.
3 MedTech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
Strong signs of rebound in base sales volumes make us optimistic about VIVO, XRAY, and PDCO's results.
ResMed (RMD) Q2 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
ResMed (RMD) reported second-quarter fiscal 2021 revenues of $800 million, up 9% from a year ago.
Smith+Nephew's (SNN) PICO sNPWT Study Outcome Encouraging
by Zacks Equity Research
Smith+Nephew's (SNN) PICO Single Use Negative Pressure Wound Therapy System (sNPWT) considerably reduces surgical site infections complications and provides better patient outcome.
Abbott (ABT) Q4 Earnings Top, Diagnostic Test Sales Solid
by Zacks Equity Research
Within Diabetes Care, Abbott (ABT) reports strong sales banking on growing demand for sensor-based continuous glucose monitoring system, FreeStyle Libre.
Boston Scientific (BSX) Enhances Core Business With Buyout
by Zacks Equity Research
Boston Scientific's (BSX) acquisition of Preventice solutions enables the former to expand rhythm management diagnostics portfolio and abilities.
Meridian Bioscience (VIVO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Meridian Bioscience (VIVO) closed at $22.60 in the latest trading session, marking a -0.88% move from the prior day.
Integra (IART) Acquires Acell, Focuses on Regenerative Space
by Zacks Equity Research
The acquisition is expected to remain accretive to Integra's (IART) revenue growth and adjusted gross margins.
Why the Earnings Surprise Streak Could Continue for Meridian Bioscience (VIVO)
by Zacks Equity Research
Meridian Bioscience (VIVO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Globus Medical (GMED) US Spine Grows, Pricing Pressure Stays
by Zacks Equity Research
Globus Medical's (GMED) recent product launches are seeing tremendous uptake.
Insulet (PODD) Omnipod DASH Reaches Canada, Global Hold Widens
by Zacks Equity Research
Insulet's (PODD) Omnipod DASH system provides 72 hours of continuous insulin therapy, simplifying lives with no more daily injection.
PerkinElmer (PKI) Receives FDA EUA for Asymptomatic Testing
by Zacks Equity Research
PerkinElmer's (PKI) RT-PCR assay to test individuals without COVID-19 symptoms acts as prime factor in controlling the spread.
Meridian Bioscience (VIVO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Meridian Bioscience (VIVO) closed at $22.13 in the latest trading session, marking a +1.33% move from the prior day.
Zacks.com featured highlights include: Vista Outdoor, Meridian Bioscience, Owens & Minor and Lakeland Industries
by Zacks Equity Research
Zacks.com featured highlights include: Vista Outdoor, Meridian Bioscience, Owens & Minor and Lakeland Industries
Meridian Bioscience, PayPal, Microsoft and JPMorgan highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Meridian Bioscience, PayPal, Microsoft and JPMorgan highlighted as Zacks Bull and Bear of the Day
Buy These 5 Low-Beta Stocks to Combat the Choppy Market
by Nilanjan Banerjee
Low-beta stocks may be able to help sail through the choppy market conditions.